SII to invest 240M pounds in UK to expand vaccine business

The Serum Institute of India (SII) will invest 240 million pounds in the UK to expand its vaccine business and create multiple jobs in the country. The investment is part of the 1 billion-pound India-UK Enhanced Trade Partnership that will create nearly 6,500 jobs in Britain.

The investment by the Adar Poonawalla-run SII will also see opening of a new sales office in the UK.

The SII has also begun phase 1 trials in the UK of a nasal vaccine against coronavirus, in partnership with Codagenix INC.

“The sales office is expected to generate new business worth over 1 billion pounds, 200 million pounds of which will be invested in the U.K. Serum’s investment will support clinical trials, research and development and possibly manufacturing of vaccines,” said the official statement from the Downing Street.

“Serum’s investment will support clinical trials, research and development and possibly manufacturing of vaccines. This will help the UK and the world to defeat the coronavirus pandemic and other deadly diseases. Serum has already started phase one trials in the UK of a one-dose nasal vaccine for coronavirus, in partnership with Codagenix INC,” the statement added.

The SII investment came after news reports claimed that Bharat has not placed fresh orders for Covid vaccines with the Serum Institute of India (SII) and Bharat BioTech since March.

Bharatiya government and the SII refuted the reports.

Poonawalla said his company has received orders for 26 crore doses from the Bharatiya government.

“As of today, we received total orders of over 26 crore doses of which we supplied more than 15 crore doses. We have also got 100 per cent advance of Rs 1,732.50 crore by GoI for the next tranche of 11 crore doses in the next few months. Another 11 crore doses would be supplied in the second channel for states and private hospitals in the next few months,” Poonawalla said in a statement.

The Financial Times had reported Poonawalla as saying that vaccine shortage could continue in Bharat till July.

The production is expected to increase from about 60 million-70 million doses a month to 100 million in July, Poonawalla was quoted as saying in the report.

Poonawalla said that his comments may have been “misinterpreted”.

(The story has been published via a syndicated feed with a few minor edits to conform to HinduPost style-guide.)


Did you find this article useful? We’re a non-profit. Make a donation and help pay for our journalism.

HinduPost is now on Telegram. For the best reports & opinion on issues concerning Hindu society, subscribe to HinduPost on Telegram.

close

Namaskar!

Sign up to receive HinduPost content in your inbox

We don’t spam! Read our privacy policy for more info.